Stem cell Biotech gets €26M to Start-off Gene Therapy Development for Children

06/05/2016 - 3 minutes

Orchard Therapeutics has just been launched with a €26M investment led by a major investor. It will be developing gene therapies for a range of blood-related disorders in children.

Based in London, Orchard Therapeutics may have just been founded, but it’s based on a long scientific track record. Its founding scientists have been pioneering the area of gene therapy in hematopoietic stem cells (that give origin to all blood cells), in reputable institutions like the Great Ormond Street Hospital (GOSH) and University College London (UCL).

Orchard is having a rather successful start, as its Series A round raised over €26M (£21M). The financing was led by F-Prime Capital, a huge investor in the life sciences, which has already invested in well-known UK biotechs like Adaptimmune, which is developing anti-cancer TCR therapies.

Orchard is developing ex-vivo autologous therapies. This means it can restore the normal gene function of the patient’s own cells in a laboratory. The cells are later transplanted back to differentiate into functioning blood cells. 

This content is available exclusively to our paying members.

Our members receive the following benefits:

  • Unlock premium articles
  • Download our industry reports
  • Remove all banner ads
  • Access 1,500+ archived posts
  • Support our independent media
Already a member? Sign in
Do you want to remove this advert? Become a member!
Do you want to remove this advert? Become a member!

Support Us

Become a Member